Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 8/20 | 0.59 |
| ▸ | CCND1 | P24385 | 8/20 | 0.59 |
| ▸ | PRKACA | P17612 | 2/20 | 0.50 |
| ▸ | PRKACG | P22612 | 2/20 | 0.50 |
| ▸ | PRKACB | P22694 | 2/20 | 0.50 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | PRKCB | P05771 | 3/20 | 0.44 |
| ▸ | CDK2 | P24941 | 3/20 | 0.42 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.42 |
| ▸ | KDR | P35968 | 3/20 | 0.41 |
| ▸ | GSK3B | P49841 | 4/20 | 0.41 |
| ▸ | GSK3A | P49840 | 3/20 | 0.41 |
| ▸ | MET | P08581 | 2/20 | 0.41 |
| ▸ | PRKCA | P17252 | 2/20 | 0.41 |
| ▸ | PRKCH | P24723 | 2/20 | 0.41 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.41 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.41 |
| ▸ | OPA1 | O60313 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6334147 | 0.86 | CDK4 (0.56) | CDK4CCND1PRKACAPRKACGPRKACB | |
| SCHEMBL6324920 | 0.86 | CDK4 (0.67) | CDK4CCND1PRKACAPRKACGPRKACB | |
| SCHEMBL10150344 | 0.86 | CDK4 (0.50) | CDK4CCND1PRKACAPRKACGPRKACB | |
| SCHEMBL6329959 | 0.86 | CDK4 (0.60) | CDK4CCND1PRKACAPRKACGPRKACB | |
| SCHEMBL6329364 | 0.85 | CDK4 (0.66) | CDK4CCND1PRKACAPRKACGPRKACB | |
| SCHEMBL3057154 | 0.85 | CDK4 (0.47) | CDK4CCND1PRKACAPRKACGPRKACB | |
| SCHEMBL9949540 | 0.84 | CDK4 (0.49) | CDK4CCND1PRKACAPRKACGPRKACB | |
| SCHEMBL6327674 | 0.83 | CDK4 (0.50) | CDK4CCND1PRKACAPRKACGPRKACB | |
| SCHEMBL6327465 | 0.83 | CDK4 (0.56) | CDK4CCND1PRKACAPRKACGPRKACB | |
| SCHEMBL6326531 | 0.83 | CDK4 (0.56) | CDK4CCND1PRKACAPRKACGPRKACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6867198-B2 | Agents and methods for the treatment of proliferative diseases | ELI LILLY AND COMPANY (US) | 2005-03-15 | — | — | US | disclosed |
| US-20030229026-A1 | Agents and methods for the treatment of proliferative diseases | ELI LILLY AND COMPANY | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229026-A1 | Agents and methods for the treatment of proliferative diseases | MKI67, CDKN1A, CDK1 | CDK4 5/4885CCND1 70/4885PRKACA 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.